Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523185 · ClinicalTrials.gov registry record · NA
A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
A NA study of Alcohol Withdrawal, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT00523185: Completed NA study of Alcohol Withdrawal, sponsored by Stanford University.
NCT00523185 is a NA study of Alcohol Withdrawal that has completed, run by Stanford University. The registered enrollment target is 55 participants, below the 80-participant average among 3 other Alcohol Withdrawal trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00523185, a NA study of Alcohol Withdrawal, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of two commonly used medications in the treatment of alcohol withdrawal, diazepam and lorazepam.
Conditions Studied
Interventions
- DRUG Lorazepam
- DRUG Diazepam
Study Locations (2)
California
- Palo Alto Veterans Affairs Hospital System - Palo Alto
- Stanford Hospital and Clinics - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2003-05 |
| Est. Completion | 2004-11 |
| Phase | NA |
What the finished NCT00523185 record still lists
NCT00523185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 80-participant average among 3 other Alcohol Withdrawal trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Alcohol Withdrawal appearing as the primary indexed condition, and to 2 interventions - of which Lorazepam is the first listed.
NCT00523185 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00523185 about?
NCT00523185 is a clinical study titled "A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal". The purpose of this study is to compare the efficacy of two commonly used medications in the treatment of alcohol withdrawal, diazepam and lorazepam.
What is the current status of trial NCT00523185?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2003-05. Estimated completion is 2004-11.
What conditions does trial NCT00523185 study?
This clinical trial studies the following conditions: Alcohol Withdrawal.
What interventions are being tested in trial NCT00523185?
The interventions under investigation include: Lorazepam (DRUG), Diazepam (DRUG).
Who is sponsoring clinical trial NCT00523185?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00523185 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Withdrawal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia